-
Je něco špatně v tomto záznamu ?
Biological and prognostic implications of biopsy upgrading for high-grade upper tract urothelial carcinoma at nephroureterectomy
S. Katayama, B. Pradere, NC. Grossman, AM. Potretzke, SA. Boorjian, A. Ghoreifi, S. Daneshmand, H. Djaladat, JP. Sfakianos, A. Mari, ZE. Khene, D. D'Andrea, N. Hayakawa, A. Breda, M. Fontana, K. Fujita, A. Antonelli, T. van Doeveren, C....
Jazyk angličtina Země Austrálie
Typ dokumentu časopisecké články
PubMed
36349904
DOI
10.1111/iju.15061
Knihovny.cz E-zdroje
- MeSH
- biopsie MeSH
- karcinom z přechodných buněk * patologie MeSH
- lidé MeSH
- nádory močového měchýře * chirurgie MeSH
- nádory močovodu * chirurgie patologie MeSH
- nefroureterektomie MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- ureteroskopie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
OBJECTIVES: Technical limitations of ureteroscopic (URS) biopsy has been considered responsible for substantial upgrading rate in upper tract urothelial carcinoma (UTUC). However, the impact of tumor specific factors for upgrading remain uninvestigated. METHODS: Patients who underwent URS biopsy were included between 2005 and 2020 at 13 institutions. We assessed the prognostic impact of upgrading (low-grade on URS biopsy) versus same grade (high-grade on URS biopsy) for high-grade UTUC tumors on radical nephroureterectomy (RNU) specimens. RESULTS: This study included 371 patients, of whom 112 (30%) and 259 (70%) were biopsy-based low- and high-grade tumors, respectively. Median follow-up was 27.3 months. Patients with high-grade biopsy were more likely to harbor unfavorable pathologic features, such as lymphovascular invasion (p < 0.001) and positive lymph nodes (LNs; p < 0.001). On multivariable analyses adjusting for the established risk factors, high-grade biopsy was significantly associated with worse overall (hazard ratio [HR] 1.74; 95% confidence interval [CI], 1.10-2.75; p = 0.018), cancer-specific (HR 1.94; 95% CI, 1.07-3.52; p = 0.03), and recurrence-free survival (HR 1.80; 95% CI, 1.13-2.87; p = 0.013). In subgroup analyses of patients with pT2-T4 and/or positive LN, its significant association retained. Furthermore, high-grade biopsy in clinically non-muscle invasive disease significantly predicted upstaging to final pathologically advanced disease (≥pT2) compared to low-grade biopsy. CONCLUSIONS: High tumor grade on URS biopsy is associated with features of biologically and clinically aggressive UTUC tumors. URS low-grade UTUC that becomes upgraded to high-grade might carry a better prognosis than high-grade UTUC on URS. Tumor specific factors are likely to be responsible for upgrading to high-grade on RNU.
Department of Pathology Medical University of Vienna Vienna Austria
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology Careggi Hospital University of Florence Florence Italy
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Urology Fundació Puigvert Autonoma University of Barcelona Barcelona Spain
Department of Urology Hospital Pontchaillou CHU Rennes Rennes France
Department of Urology Icahn School of Medicine at Mount Sinai Hospital New York City New York USA
Department of Urology Mayo Clinic Rochester Minnesota USA
Department of Urology Osaka University Graduate School of Medicine Osaka Japan
Department of Urology St Marianna University School of Medicine Kanagawa Japan
Department of Urology The Jikei University School of Medicine Tokyo Japan
Department of Urology University Hospital Zurich Zurich Switzerland
Department of Urology University of Texas Southwestern Medical Center Dallas Texas USA
Department of Urology Weill Cornell Medical College New York City New York USA
GRC 5 Predictive Onco Uro AP HP Urology Pitie Salpetriere Hospital Sorbonne University Paris France
Hourani Center for Applied Scientific Research Al Ahliyya Amman University Amman Jordan
Institute for Urology and Reproductive Health Sechenov University Moscow Russia
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004783
- 003
- CZ-PrNML
- 005
- 20230425171722.0
- 007
- ta
- 008
- 230418s2023 at f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/iju.15061 $2 doi
- 035 __
- $a (PubMed)36349904
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a at
- 100 1_
- $a Katayama, Satoshi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan $1 https://orcid.org/0000000283772457
- 245 10
- $a Biological and prognostic implications of biopsy upgrading for high-grade upper tract urothelial carcinoma at nephroureterectomy / $c S. Katayama, B. Pradere, NC. Grossman, AM. Potretzke, SA. Boorjian, A. Ghoreifi, S. Daneshmand, H. Djaladat, JP. Sfakianos, A. Mari, ZE. Khene, D. D'Andrea, N. Hayakawa, A. Breda, M. Fontana, K. Fujita, A. Antonelli, T. van Doeveren, C. Steinbach, K. Mori, E. Laukhtina, M. Rouprêt, V. Margulis, PI. Karakiewicz, M. Araki, E. Compérat, Y. Nasu, SF. Shariat
- 520 9_
- $a OBJECTIVES: Technical limitations of ureteroscopic (URS) biopsy has been considered responsible for substantial upgrading rate in upper tract urothelial carcinoma (UTUC). However, the impact of tumor specific factors for upgrading remain uninvestigated. METHODS: Patients who underwent URS biopsy were included between 2005 and 2020 at 13 institutions. We assessed the prognostic impact of upgrading (low-grade on URS biopsy) versus same grade (high-grade on URS biopsy) for high-grade UTUC tumors on radical nephroureterectomy (RNU) specimens. RESULTS: This study included 371 patients, of whom 112 (30%) and 259 (70%) were biopsy-based low- and high-grade tumors, respectively. Median follow-up was 27.3 months. Patients with high-grade biopsy were more likely to harbor unfavorable pathologic features, such as lymphovascular invasion (p < 0.001) and positive lymph nodes (LNs; p < 0.001). On multivariable analyses adjusting for the established risk factors, high-grade biopsy was significantly associated with worse overall (hazard ratio [HR] 1.74; 95% confidence interval [CI], 1.10-2.75; p = 0.018), cancer-specific (HR 1.94; 95% CI, 1.07-3.52; p = 0.03), and recurrence-free survival (HR 1.80; 95% CI, 1.13-2.87; p = 0.013). In subgroup analyses of patients with pT2-T4 and/or positive LN, its significant association retained. Furthermore, high-grade biopsy in clinically non-muscle invasive disease significantly predicted upstaging to final pathologically advanced disease (≥pT2) compared to low-grade biopsy. CONCLUSIONS: High tumor grade on URS biopsy is associated with features of biologically and clinically aggressive UTUC tumors. URS low-grade UTUC that becomes upgraded to high-grade might carry a better prognosis than high-grade UTUC on URS. Tumor specific factors are likely to be responsible for upgrading to high-grade on RNU.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nefroureterektomie $7 D000074682
- 650 12
- $a karcinom z přechodných buněk $x patologie $7 D002295
- 650 12
- $a nádory močového měchýře $x chirurgie $7 D001749
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a ureteroskopie $7 D018666
- 650 12
- $a nádory močovodu $x chirurgie $x patologie $7 D014516
- 650 _2
- $a biopsie $7 D001706
- 650 _2
- $a retrospektivní studie $7 D012189
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Grossman, Nico C $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, University Hospital Zurich, Zurich, Switzerland $1 https://orcid.org/0000000186986461
- 700 1_
- $a Potretzke, Aaron M $u Department of Urology, Mayo Clinic, Rochester, Minnesota, USA $1 https://orcid.org/0000000346191773
- 700 1_
- $a Boorjian, Stephen A $u Department of Urology, Mayo Clinic, Rochester, Minnesota, USA
- 700 1_
- $a Ghoreifi, Alireza $u Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA $1 https://orcid.org/0000000273687240
- 700 1_
- $a Daneshmand, Sia $u Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA
- 700 1_
- $a Djaladat, Hooman $u Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA
- 700 1_
- $a Sfakianos, John P $u Department of Urology, Icahn School of Medicine at Mount Sinai Hospital, New York City, New York, USA
- 700 1_
- $a Mari, Andrea $u Department of Urology, Careggi Hospital, University of Florence, Florence, Italy
- 700 1_
- $a Khene, Zine-Eddine $u Department of Urology, Hospital Pontchaillou, CHU Rennes, Rennes, France
- 700 1_
- $a D'Andrea, David $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $1 https://orcid.org/0000000316251077
- 700 1_
- $a Hayakawa, Nozomi $u Department of Urology, St. Marianna University School of Medicine, Kanagawa, Japan
- 700 1_
- $a Breda, Alberto $u Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Barcelona, Spain
- 700 1_
- $a Fontana, Matteo $u Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Barcelona, Spain
- 700 1_
- $a Fujita, Kazutoshi $u Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan
- 700 1_
- $a Antonelli, Alessandro $u Urology Unit AUOI Verona, Department of Surgery, Dentistry, Pediatrics and Gynecology, University of Verona, Verona, Italy
- 700 1_
- $a van Doeveren, Thomas $u Department of Urology, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Rotterdam, The Netherlands
- 700 1_
- $a Steinbach, Christina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Mori, Keiichiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/0000000261476569
- 700 1_
- $a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia $1 https://orcid.org/0000000289530272
- 700 1_
- $a Rouprêt, Morgan $u GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France
- 700 1_
- $a Margulis, Vitaly $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
- 700 1_
- $a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Quebec, Canada
- 700 1_
- $a Araki, Motoo $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan $1 https://orcid.org/0000000231722482
- 700 1_
- $a Compérat, Eva $u GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France $u Department of Pathology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Nasu, Yasutomo $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan $u Department of Urology, Weill Cornell Medical College, New York City, New York, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
- 773 0_
- $w MED00007209 $t International journal of urology : official journal of the Japanese Urological Association $x 1442-2042 $g Roč. 30, č. 1 (2023), s. 63-69
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36349904 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425171718 $b ABA008
- 999 __
- $a ok $b bmc $g 1925085 $s 1190992
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 30 $c 1 $d 63-69 $e 20221109 $i 1442-2042 $m International journal of urology $n Int J Urol $x MED00007209
- LZP __
- $a Pubmed-20230418
